DexCom (NASDAQ:DXCM) Insider Kevin Sayer Sells 26,759 Shares

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,759 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Down 0.1%

Shares of DXCM stock traded down $0.09 on Tuesday, hitting $72.01. 5,311,632 shares of the stock were exchanged, compared to its average volume of 5,319,043. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $27.79 billion, a P/E ratio of 30.77, a price-to-earnings-growth ratio of 1.19 and a beta of 1.40. The business has a 50-day moving average of $63.72 and a 200 day moving average of $66.09. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 earnings per share. Equities analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Barclays restated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of DexCom in a report on Monday, March 9th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Finally, Truist Financial restated a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $82.21.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Gradient Investments LLC increased its position in DexCom by 13.8% during the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after buying an additional 40,343 shares during the last quarter. Nordea Investment Management AB increased its position in DexCom by 118.6% during the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after buying an additional 137,986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after buying an additional 21,352 shares during the last quarter. NEOS Investment Management LLC increased its position in DexCom by 58.7% during the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock worth $11,842,000 after buying an additional 65,066 shares during the last quarter. Finally, Banco Santander S.A. increased its position in DexCom by 28.9% during the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock worth $16,843,000 after buying an additional 56,062 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.